Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility

被引:23
作者
Klemens, SP [1 ]
Sharpe, CA [1 ]
Cynamon, MH [1 ]
机构
[1] VET AFFAIRS MED CTR, SYRACUSE, NY 13210 USA
关键词
D O I
10.1128/AAC.40.1.14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The activity of pyrazinamide (PZA) against eight isolates of Mycobacterium tuberculosis in a murine infection model was evaluated. M. tuberculosis isolates with various degrees of in vitro susceptibility to PZA (MIG range, 32 to >2,048 mu g/ml) were used. Four-week-old female mice were infected intravenously with approximately 10(7) viable M. tuberculosis organisms, PZA at 150 mg/kg of body weight was started 1 day postinfection and given 5 days/week for 4 weeks. Infected but untreated mice were compared,vith PZA-treated mice. Mice were sacrificed at the completion of the treatment period, and viable cell counts were determined from homogenates of spleens and right lungs, PZA had activity in the murine test system against M. tuberculosis isolates for which the MICs were less than or equal to 256 mu g/ml. However, there was an inconsistent correlation between the absolute MICs and the reductions in organ viable cell counts, Studies with drug-resistant A(l. tuberculosis isolates with an isogenic background would improve evaluation of drug efficacy in the murine test system. Further evaluation of antimycobacterial agents against monodrug-resistant isolates will provide data that will be useful for development of algorithms for treatment of infection with drug-resistant organisms.
引用
收藏
页码:14 / 16
页数:3
相关论文
共 22 条
[1]   TREATMENT OF TUBERCULOSIS AND TUBERCULOSIS INFECTION IN ADULTS AND CHILDREN [J].
BASS, JB ;
FARER, LS ;
HOPEWELL, PC ;
OBRIEN, R ;
JACOBS, RF ;
RUBEN, F ;
SNIDER, DE ;
THORNTON, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (05) :1359-1374
[2]   SUSCEPTIBILITY OF MYCOBACTERIUM-TUBERCULOSIS TO PYRAZINAMIDE AND ITS RELATIONSHIP TO PYRAZINAMIDASE ACTIVITY [J].
BUTLER, WR ;
KILBURN, JO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (04) :600-601
[3]   DRUG-TREATMENT OF TUBERCULOSIS - 1992 [J].
DAVIDSON, PT ;
LE, HQ .
DRUGS, 1992, 43 (05) :651-673
[4]  
DESSAU FI, 1952, AM REV TUBERC PULM, V65, P519
[5]  
ELLARD G A, 1969, Tubercle, V50, P144, DOI 10.1016/0041-3879(69)90020-8
[6]   CLINICAL PRESENTATION AND OUTCOME OF PATIENTS WITH HIV-INFECTION AND TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT BACILLI [J].
FISCHL, MA ;
DAIKOS, GL ;
UTTAMCHANDANI, RB ;
POBLETE, RB ;
MORENO, JN ;
REYES, RR ;
BOOTA, AM ;
THOMPSON, LM ;
CLEARY, TJ ;
OLDHAM, SA ;
SALDANA, MJ ;
LAI, SH .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (03) :184-190
[7]   STERILIZING VALUE OF RIFAMPICIN AND PYRAZINAMIDE IN EXPERIMENTAL SHORT COURSE CHEMOTHERAPY [J].
GROSSET, J .
TUBERCLE, 1978, 59 (04) :287-297
[8]  
Grosset J, 1990, Bull Int Union Tuberc Lung Dis, V65, P86
[9]  
HEIFERTS LB, 1991, DRUG SUSCEPTIBILITY, P109
[10]   DOES PYRAZINOIC ACID AS AN ACTIVE MOIETY OF PYRAZINAMIDE HAVE SPECIFIC ACTIVITY AGAINST MYCOBACTERIUM-TUBERCULOSIS [J].
HEIFETS, LB ;
FLORY, MA ;
LINDHOLMLEVY, PJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1252-1254